Biology of breast cancer during pregnancy using genomic profiling

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages 545-554

  Azim Jr , Hatem A ^a   Brohée, Sylvain ^a   Peccatori, Fedro A ^b   Desmedt, Christine ^a   Loi, Sherene ^c,d   Lambrechts, Diether ^e,f   Dell'Orto, Patrizia ^b   Majjaj, Samira ^a   Jose, Vinu ^a   Rotmensz, Nicole ^b   Ignatiadis, Michail ^a,g   Pruneri, Giancarlo ^b   Piccart, Martine ^g   Viale, Giuseppe ^b   Sotiriou, Christos ^a,g  

^a JULES BORDET INSTITUTE   (Belgium)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f KU Leuven   (Belgium)

^g UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Biology; Breast cancer during pregnancy; Breast microenvironment; Gene expression profiling; IGF1; Mutations; PD1; PDL1; Young women

Indexed keywords

BETA CATENIN; G PROTEIN COUPLED RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; PROTEIN RET; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PREGNANCY; SOMATIC MUTATION; THIRD TRIMESTER PREGNANCY; TRANSCRIPTOMICS; TUMOR GENE; ANIMAL; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; MUTATION;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MICE; MUTATION; PREGNANCY;

EID: 84905986858     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0111     Document Type: Article

References (50)

1. Albrektsen G, Heuch I, Hansen S & Kvale G 2005 Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. British Journal of Cancer 92 167-175. (doi:10.1038/sj.bjc. 6602302)
2. Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, Willemsen MA, Kapusta L, Van Calster B, Wouters H et al. 2012 Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncology 13 256-264. (doi:10.1016/S1470-2045(11)70363-1)
3. Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B et al. 2013 Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an International Collaborative Study. Journal of Clinical Oncology 31 2532-2539. (doi:10.1200/JCO.2012.45.6335)
4. Anderson SM, Rudolph MC, McManaman JL & Neville MC 2007 Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis!. Breast Cancer Research 9 204. (doi:10.1186/bcr1653)
5. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C & Loi S 2012a Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clinical Cancer Research 18 1341-1351. (doi:10.1158/1078-0432.CCR-11-2599)
6. Azim HA Jr, Botteri E, Renne G, Dell'orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M et al. 2012b The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study. Acta Oncologica 51 653-661. (doi:10.3109/0284186X.2011. 636069)
7. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A et al. 2006 Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 353-357. (doi:10.1038/nature04296)
8. Bolstad BM, Irizarry RA, Astrand M & Speed TP 2003 A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19 185-193. (doi:10.1093/bioinformatics/19.2. 185)
9. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A et al. 2010 Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Annals of Oncology 21 1974-1981. (doi:10.1093/annonc/mdq072)
10. Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S & Usmani A 2010 Breast cancer during pregnancy: maternal and fetal outcomes. Cancer Journal 16 76-82. (doi:10.1097/PPO.0b013e3181ce46f9)
11. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP et al. 2012 Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Research and Treatment 131 1061-1066. (doi:10.1007/s10549- 011-1872-9)
12. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM & El-Ashry D 2006 Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors. Cancer Research 66 3903-3911. (doi:10.1158/0008-5472.CAN-05-4363)
13. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK & Lee AV 2008 Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. Journal of Clinical Oncology 26 4078-4085. (doi:10.1200/JCO.2007.13.4429)
14. D'Addio F, Riella LV, Mfarrej BG, Chabtini L, Adams LT, Yeung M, Yagita H, Azuma M, Sayegh MH & Guleria I 2011 The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. Journal of Immunology 187 4530-4541. (doi:10.4049/jimmunol.1002031)
15. D'Cruz CM, Moody SE, Master SR, Hartman JL, Keiper EA, Imielinski MB, Cox JD, Wang JY, Ha SI, Keister BA et al. 2002 Persistent parity-induced changes in growth factors, TGF-β3, and differentiation in the rodent mammary gland. Molecular Endocrinology 16 2034-2051. (doi:10.1210/me.2002-0073)
16. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M & Sotiriou C 2008 Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clinical Cancer Research 14 5158-5165. (doi:10.1158/1078-0432.CCR-07-4756)
17. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al. 2002 Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine 8 793-800. (doi:10.1038/nm0902-1039c)
18. Dorsam RT & Gutkind JS 2007 G-protein-coupled receptors and cancer. Nature Reviews. Cancer 7 79-94. (doi:10.1038/nrc2069)
19. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E et al. 2009 Astroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine 15 68-74. (doi:10.1038/nm.1908)
20. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J & Sotiriou C 2012 A three-gene model to robustly identify breast cancer molecular subtypes. Journal of the National Cancer Institute 104 311-325. (doi:10.1093/jnci/djr545)
21. Hernandez LL, Gregerson KA & Horseman ND 2012 Mammary gland serotonin regulates parathyroid hormone-related protein and other bone-related signals. American Journal of Physiology. Endocrinology and Metabolism 302 E1009-E1015. (doi:10.1152/ajpendo.00666.2011)
22. Huang da W, Sherman BT & Lempicki RA 2009 Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research 37 1-13. (doi:10.1093/nar/gkn923)
23. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T & Minato N 2002 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS 99 12293-12297. (doi:10.1073/pnas. 192461099)
24. Johannsson O, Loman N, Borg A & Olsson H 1998 Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 352 1359-1360. (doi:10.1016/S0140-6736(05)60750-7)
25. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, Lewis MT, Gottardis MM, Wong TW, Attar RM et al. 2007 Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-κB and snail. Molecular and Cellular Biology 27 3165-3175. (doi:10.1128/MCB.01315-06)
26. Kvachnina E, Liu G, Dityatev A, Renner U, Dumuis A, Richter DW, Dityateva G, Schachner M, Voyno-Yasenetskaya TA & Ponimaskin EG 2005 5-HT7 receptor is coupled to Gα subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. Journal of Neuroscience 25 7821-7830. (doi:10.1523/JNEUROSCI.1790-05.2005)
27. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A et al. 2009 Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine 15 907-913. (doi:10.1038/nm.2000)
28. Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, Mittendorf EA, Barnett C, Gonzalez-Angulo AM, Hortobagyi GN et al. 2013 Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist 18 369-376. (doi:10.1634/theoncologist.2012-0340)
29. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A et al. 2010 PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. PNAS 107 10208-10213. (doi:10.1073/pnas.0907011107)
30. Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, Fehm T, Van Calsteren K, Linn SC, Schlehe B et al. 2012 Treatment of breast cancer during pregnancy: an observational study. Lancet Oncology 13 887-896. (doi:10.1016/S1470-2045(12)70261-9)
31. Macias H & Hinck L 2012 Mammary gland development. Wiley Interdisciplinary Reviews. Developmental Biology 1 533-557. (doi:10.1002/wdev. 35)
32. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR et al. 2004 mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine 10 594-601. (doi:10.1038/nm1052)
33. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL & Chodosh LA 1995 The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature Genetics 11 17-26. (doi:10.1038/ng0995-17)
34. Marshall AM, Nommsen-Rivers LA, Hernandez LL, Dewey KG, Chantry CJ, Gregerson KA & Horseman ND 2010 Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. Journal of Clinical Endocrinology and Metabolism 95 837-846. (doi:10.1210/jc.2009-1575)
35. Matsuda M, Imaoka T, Vomachka AJ, Gudelsky GA, Hou Z, MistryM, Bailey JP, Nieport KM, Walther DJ, Bader M et al. 2004 Serotonin regulates mammary gland development via an autocrine-paracrine loop. Developmental Cell 6 193-203. (doi:10.1016/S1534-5807(04)00022-X)
36. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN et al. 2001 Involvement of chemokine receptors in breast cancer metastasis. Nature 410 50-56. (doi:10.1038/35065016)
37. Narod SA 2012 Breast cancer in young women. Nature Reviews. Clinical Oncology 9 460-470. (doi:10.1038/nrclinonc.2012.102)
38. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA et al. 2012 Mutational processes molding the genomes of 21 breast cancers. Cell 149 979-993. (doi:10.1016/j.cell. 2012.04.024)
39. Pai VP, Marshall AM, Hernandez LL, Buckley AR & Horseman ND 2009 Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Research 11 R81. (doi:10.1186/bcr2448)
40. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology 27 1160-1167. (doi:10.1200/JCO.2008.18.1370)
41. Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V & Pentheroudakis G 2013 Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 24 (Suppl 6) vi160-vi170. (doi:10.1093/annonc/mdt199)
42. Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen M, Staaf J, Jonsson G, Pires MM, Maurer M, Holm K et al. 2008 Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genetics 40 102-107. (doi:10.1038/ng.2007.39)
43. Smith J, Axelrod D, Singh B & Kleinberg D 2011 Prevention of breast cancer: the case for studying inhibition of IGF-1 actions. Annals of Oncology 22 (Suppl 1) i50-i52. (doi:10.1093/annonc/mdq666)
44. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B et al. 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute 98 262-272. (doi:10.1093/jnci/djj052)
45. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR et al. 2012 The landscape of cancer genes and mutational processes in breast cancer. Nature 486 400-404. (doi:10.1038/nature11017)
46. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO & Caldas C 2007 An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biology 8 R157. (doi:10.1186/gb-2007-8-8-r157)
47. Thomas P, Pang Y, Filardo EJ & Dong J 2005 Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 624-632. (doi:10.1210/en.2004-1064)
48. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. 2012 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine 366 2443-2454. (doi:10.1056/NEJMoa1200690)
49. Varemo L, Nielsen J & Nookaew I 2013 Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods. Nucleic Acids Research 41 4378-4391. (doi:10.1093/nar/gkt111)
50. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530-536. (doi:10.1038/415530a)